Jean George - 14 Feb 2024 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role: Director
Signature: /s/ David Gaiero, as attorney-in-fact for Jean George
Issuer symbol: N/A
Transactions as of: 14 Feb 2024
Net transactions value: +$23,914
Form type: 4
Filing time: 16 Feb 2024, 16:00:12 UTC
Previous filing: 07 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Options Exercise	$23,914	+14,150		$1.69	14,150	14 Feb 2024	Direct
holding	CYT	Common Stock						2,444,265	14 Feb 2024	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Stock Option (Right to Buy)	Options Exercise	$0	-14,150	-100%	$0.000000^*	0	14 Feb 2024	Common Stock	14,150	$1.69	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.

Content

Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.